The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
Open accessAbstract
Background X-linked hypophosphatemia in children is characterized by elevated serum FGF23, hypophosphatemia, rickets, lower extremity bowing, and growth impairment. We compared the efficacy and safety of continuing conventional therapy, consisting of oral phosphate and active vitamin D, versus switching to burosumab, a fully human monoclonal antibody against FGF23, in pediatric X-linked hypophosphatemia. Methods In this randomised, active-controlled, open-label, phase 3 trial at 16 clinical sites, we enrolled children with X-linked hypophosphataemia aged 1–12 years. Key eligibility criteria were a total Thacher rickets severity score of at least 2·0, fasting serum phosphorus lower than 0·97 mmol/L (3·0 mg/dL), confirmed PHEX (phosphate-regulating endopeptidase homolog, X-linked) mutation or variant of unknown significance in the patient or a family member with appropriate X-linked dominant inheritance, and receipt of conventional therapy for at least 6 consecutive months for children younger than 3 years or at least 12 consecutive months for children older than 3 years. Eligible patients were randomly assigned (1:1) to receive either subcutaneous burosumab starting at 0·8 mg/kg every 2 weeks (burosumab group) or conventional therapy prescribed by investigators (conventional therapy group). Both interventions lasted 64 weeks. The primary endpoint was change in rickets severity at week 40, assessed by the Radiographic Global Impression of Change global score. All patients who received at least one dose of treatment were included in the primary and safety analyses. The trial is registered with ClinicalTrials.gov, number NCT02915705. Findings Recruitment took place between Aug 3, 2016, and May 8, 2017. Of 122 patients assessed, 61 were enrolled. Of these, 32 (18 girls, 14 boys) were randomly assigned to continue receiving conventional therapy and 29 (16 girls, 13 boys) to receive burosumab. For the primary endpoint at week 40, patients in the burosumab group had significantly greater improvement in Radiographic Global Impression of Change global score than did patients in the conventional therapy group (least squares mean +1·9 [SE 0·1] with burosumab vs +0·8 [0·1] with conventional therapy; difference 1·1, 95% CI 0·8–1·5; p<0·0001). Treatment-emergent adverse events considered possibly, probably, or definitely related to treatment by the investigator occurred more frequently with burosumab (17 [59%] of 29 patients in the burosumab group vs seven [22%] of 32 patients in the conventional therapy group). Three serious adverse events occurred in each group, all considered unrelated to treatment and resolved. Interpretation Significantly greater clinical improvements were shown in rickets severity, growth, and biochemistries among children with X-linked hypophosphataemia treated with burosumab compared with those continuing conventional therapy. Funding Ultragenyx Pharmaceutical Inc. and Kyowa Kirin International
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000
Kuczmarski, R. J., Ogden, C. L., Guo, S. S., Strawn, L. G., Flegal, K. M., & Mei, Z. (2002) · Cited by 6,426
2000 CDC Growth Charts for the United States: methods and development.
Kuczmarski, R. J., Ogden, C. L., Guo, S. S., Grummer‐Strawn, L. M., Flegal, K. M., Mei, Z., Wei, R. X., Curtin, L. R., Roche, A. F., & Johnson, C. L. (2002) · PubMed · Cited by 3,716
Clinical longitudinal standards for height and height velocity for North American children
Tanner, J. M., & Davies, P. S. W. (1985) · The Journal of Pediatrics · doi:10.1016/s0022-3476(85)80501-1 · Cited by 1,092
Georges, G. T., Nájera, O., Sowers, K., & Sowers, J. R. (2017) · Cardiorenal Medicine · doi:10.1159/000449476 · Cited by 680
Six-Minute Walk Test in Children and Adolescents
Geiger, R., Strasak, A., Treml, B., Gasser, K., Kleinsasser, A., Fischer, V., Geiger, H., Loeckinger, A., & Stein, J. I. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.12.052 · Cited by 653
A clinician's guide to X-linked hypophosphatemia
Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M., & Insogna, K. L. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.340 · Cited by 612
Self-citationBurosumab Therapy in Children with X-Linked Hypophosphatemia
Carpenter, T. O., Whyte, M. P., Imel, E. A., Boot, A. M., Högler, W., Linglart, A., Padidela, R., van’t Hoff, W., Mao, M., Chen, C.-Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714641 · Cited by 479
Self-citationTherapeutic management of hypophosphatemic rickets from infancy to adulthood
Linglart, A., Biosse-Duplan, M., Briot, K., Chaussain, C., Esterle, L., Guillaume-Czitrom, S., Kamenicky, P., Nevoux, J., Prié, D., Rothenbuhler, A., et al. (2014) · Endocrine Connections · doi:10.1530/ec-13-0103 · Cited by 331
Glorieux, F. H., Marie, P. J., Pettifor, J. M., & Delvin, E. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198010303031802 · Cited by 287
Self-citationEffects of Therapy in X-Linked Hypophosphatemic Rickets
Verge, C. F., Lam, A., Simpson, J. M., Cowell, C. T., Howard, N. J., & Silink, M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112263252604 · Cited by 250
Cited by
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y., Wang, S., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.05.004 · Cited by 10
“In the clinical trials, Burosumab could restore phosphate homeostasis in patients with XLH, thereby improving the prognosis for rickets, lower limb deformities and linear growth in children and pseudofracture healing in adults [15,16].”
Background
Metadata
- Authors
- Imel, E. A., Glorieux, F. H., Whyte, M. P., Munns, C. F., Ward, L. M., Nilsson, O., Simmons, J. H., Padidela, R., Namba, N., Cheong, H. I., Pitukcheewanont, P., Sochett, E., Högler, W., Muroya, K., Tanaka, H., Gottesman, G. S., Biggin, A., Perwad, F., Mao, M., Chen, C.-Y., Skrinar, A., San Martin, J., & Portale, A. A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 393
- Issue
- 10189
- Pages
- 2416-2427
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2946559089
- Cited by
- 379
- References
- 21
- FWCI
- 29.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)30654-3
- The paper
- Imel, E. A., Glorieux, F. H., Whyte, M. P., Munns, C. F., Ward, L. M., Nilsson, O., Simmons, J. H., Padidela, R., Namba, N., Cheong, H. I., Pitukcheewanont, P., Sochett, E., Högler, W., Muroya, K., Tanaka, H., Gottesman, G. S., Biggin, A., Perwad, F., Mao, M., . . . Portale, A. A. (2019). Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)30654-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.